72 results about "Paroxysmal AF" patented technology

The invention discloses a traditional Chinese medicine combination and a preparation method thereof for chronic enteritis treatment; the traditional Chinese medicine combination mainly includes the following raw medicines: crude radix astragali, Chinese yam, bighead atractylodes rhizome, rhizoma smilacis glabrae, honeysuckle, taraxacum officinale root, medicated leaven, burnt malt, atraotydin, mangnolia officinalis, dried tangerine or orange peel, plantain seed, scutellaria baicalensis, the rhizome of Chinese goldthread, limonite, semen euryales, fructus rosae laevigatae, liriope, fructus amomi, starwort root, schisandra, acorus gramineus, medlar, cyperus rotundus and the like The traditional Chinese medicine combination can be prepared into any type of common oral preparation according to the conventional traditional Chinese medicine preparation method. The invention can significantly improve the symptoms of chronic diarrhea, paroxysmal abdominal pain, dyspepsia, indigestion, loose stool, abdominal distension, emaciation, limb fatigue and doldrums, and also has definite clinical curative effect, significant curative and quick effect. As the traditional Chinese medicine combination basically combines medicinal and edible medicine sources specified in the National Formulary, the traditional Chinese medicine combination has low cost and basically has no toxic and side effect.

Immunosorbents, kits and compositions for diagnosing a central nervous system disorder, particularly paroxysmal cerebral discharges and epilepsy, comprising measuring the concentration of GluR1 or fragment thereof and/or GluR1 antibodies in a biological sample from a human subject. The method is particularly useful for identifying individuals that are at risk for brain related seizures and epilepsy, for distinguishing epilepsy from pseudo-epilepsy and epilepsy-like disorders, for following up after anticonvulsive treatment, and for the adjustment of adequate therapy and doses.

This invention provides methods for alleviating paroxysmal disorders in an animal, particularly epilepsy, by modulating glycolysis in brain cells.

The invention discloses an intelligent analysis method and system of paroxysmal atrial fibrillation based on a difference time scatter diagram. The method includes a training stage and a detection stage; the training stage includes the steps: A1) collecting original ECG training data; A2) drawing the difference time scatter diagram of the training stage; A3) labeling the difference time scatter diagram with an atrial fibrillation attack label and a non-atrial fibrillation attack label; and A4) training a convolution neural network model. The detection stage includes the steps: B1) collecting original ECG detection data; B2) drawing the difference time scatter diagram of the detection stage; and B3) inputting the difference time scatter diagram of the detection stage to the convolution neural network model and outputting intelligent analysis results of paroxysmal atrial fibrillation. The intelligent diagnosis of paroxysmal atrial fibrillation can be realized and the detection of subclinical atrial fibrillation patients can be realized by using the method for classification by the differential time scatter diagram.

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement factor B (CFB) gene, the complement component C3 gene, and the complement component C9 gene and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of CFB, C9 and/or C3 and to treat subjects having a complement component-associated disease, e.g., paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

A heart stimulator has a stimulation energy delivering assembly, including at least one lead adapted for implantation in contact with cardiac tissue, and an atrial arrhythmia detector, and a control unit connected to the stimulation energy delivering assembly and to the detector. The control unit controls the stimulation energy delivering assembly to deliver at least one atrial arrhythmia abolishing therapy and, if continued atrial arrhythmia is detected, to deliver antithrombus stimulation energy pulses of lower energy than a defibrillation shock, but with different timing and with sufficient energy for producing atrial contraction for increasing hemodynamic blood transportation away from the atrium and for preventing thrombi formation in the atrium. For a patient suffering from a chronic or paroxysmal non-curable atrial arrhythmia, the control unit controls the stimulation energy delivering assembly to deliver the antithrombus energy without any preceding arrhythmia abolishing therapy.

A combination of an antacid, alginate, and a histamine H₂-receptor antagonist, and methods of using the same for providing fast and lasting relief of symptoms of episodic heartburn are provided.

The invention discloses a method for establishing a dog vagal nerve trunk stimulation-induced AF (atrial fibrillation) experimental model. The method comprises the following steps: 1, narcotization of an animal; 2, placement of an electrophysiological mapping catheter; 3, electrophysiological examination; and 4, induction and termination of AF. The method for establishing the dog vagal nerve trunk stimulation-induced AF experimental model has the beneficial effects that an acute AF animal model is manufactured through accurately positioning and stimulating dog's vagal nerve trunk, vagal nerve plexus in blood vessels and an epicardial fat pad, so that the induction rate and the stability of the model are improved; the time of duration is increased; and the manufactured dog vagus nerve-mediated AF model has the characteristics of atrial muscle and pulmonary vein electrophysiological change characteristics similarity to paroxysmal AF patients.

The invention provides an application of traditional Chinese medicine composite in preparing medicine treating paroxysmal atrial fibrillation. Clinic trials prove that the traditional Chinese medicine composite has the functions of tonifying qi and yin, promoting blood circulation, removing meridian obstruction, clearing away the heart fire and tranquillizing, can be used for treating paroxysmal atrial fibrillation, can obviously improve clinic symptoms and performs favourable treating effect.

To provide a therapeutic agent for diseases associated with Nav 1.7, specifically diseases such as neuropathic pain, nociceptive pain, inflammatory pain, small fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, urination disorders and multiple sclerosis. Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (In the formula, each of R1a,R1b, R1c and R1d represents a hydrogen atom, a halogen atom, a cyano group, a C1-4 alkyl group, a C1-4 alkoxy group or the like, provided that at least one of the R1a, R1b, R1c and R1d moieties represents a C6-10 aryl group, a C6-10 aryloxy group or the like; each of R2 and R3 represents a hydrogen atom, a C1-6 alkyl group, a C3-10 cycloalkyl group or the like; R4 represents a hydrogen atom, a C1-6 alkyl group, a C3-7 cycloalkyl group or the like; m represents 1, 2 or 3; L represents a CR7R8 group; and each of R7 and R8 represents a hydrogen atom, a hydroxyl group, a C1-4 alkyl group, a C1-4 alkoxy group or the like.)

The invention discloses an anti-C5 full-human derived single-chain antibody C5B3 and application thereof. The anti-C5 full-human derived single-chain antibody C5B3 has a DNA (Deoxyribonucleic Acid) sequence as shown in SEQ ID NO:1. By adopting the antibody, formation of a membrane attacking composition in an inflammation reaction process can be remarkably inhibited, so that damage caused in the inflammation reaction process can be reduced. The invention further discloses application of the anti-C5 full-human derived single-chain antibody C5B3 in preparing medicines for treating autoimmune diseases such as ophthalmoneuromyelitis, multiple sclerosis, systemic lupus erythematosus and myasthenia gravis and/or inflammation and diseases with related symptoms caused by paroxysmal nocturnal hemoglobinuria (PNH), atypical haemolytic uraemic syndrome (AHU) and trauma.

The invention discloses a traditional Chinese medicine composition for preventing and treating paroxysmal atrial fibrillation as well as superfine powder water pills and application thereof. The medicine is prepared into the superfine powder water pills from aconitum napellus, cassia twig, raw oyster shell, rhizoma alismatis, cortex lycii radicis, magnets, radix stephaniae tetrandrae, beautiful sweetgum fruit, processed polygala tenuifolia, white mulberry root-bark, sappanwood, amber powder, radix ophiopogonis, ramulus mori, radix puerariae, tetrapanax papyriferus, turtle shell, dung beetle, pine nuts, crude dragon bone, tortoise plastron, rhizoma nardostachyos, fried wild jujube seeds, raw jujube kernels, leech, safflower, coptis chinensis, scutellaria baicalensis, American ginseng, schisandra chinensis, morinda officinalis, radices stellariae dichotomae and root of rehmannia. The traditional Chinese medicine composition disclosed by the invention is used for preventing and treating arrhythmia, accords with traditional Chinese medicine syndrome patterns such as yin-yang deficiency and deficient yang with upper manifestation, is mainly specified at patients with persistent atrial fibrillation and various arrhythmia such as palpitation, short of breath, fear of cold and the like, and is obvious in curative effects and excellent in clinical effect, and the prepared superfine powder water pills are small in size and convenient to take and carry.

The invention provides a screening kit for paroxysmal supraventricular tachycardia. The screening kit comprises an optional reagent for detecting a human CACNA1B gene c.1700 A>G mutation site, whereinthe c.1700A>G mutation site of the CACNA1B gene refers to a mutation site where the 1700th basic group of the coding region of the CACNA1B gene is changed from A to G. The kit provided by the invention is designed based on the significant correlation between the c.1700A>G mutation of the CACNA1B gene and paroxysmal supraventricular tachycardia; the screening kit for paroxysmal supraventricular tachycardia is a first molecular screening kit for paroxysmal supraventricular tachycardia, can assist in diagnosis of paroxysmal supraventricular tachycardia (especially atrioventricular nodal reentrant tachycardia), is beneficial to prenatal and postnatal care, can guide doctors to apply medicines according to symptoms and has good application prospects.

The present disclosure provides methods of treating paroxysmal nocturnal hemoglobinuria (PNH) in subjects with varying exposure to eculizumab by administering R5000. The methods include methods of switching subjects from treatment with eculizumab to R5000.

The invention provides compounds which are selective PDE2 inhibitors for use in the treatment of tachycardia or tachyarrhythmia Such compounds are particularly suitable for use in the treatment of any of the following conditions: atrial tachycardia, atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, premature ventricular contractions (PVCs), ventricular fibrillation and ventricular tachycardia, and may be used alone or in combination therapy with other conventional cardiovascular drugs, e.g. beta-blockers. In particular, the invention provides compounds which are selective PDE2 inhibitors for use in the treatment of ventricular tachycardia in patients who are suffering from, or who are at risk of suffering from heart failure, CPVT or long QT syndrome.

The invention relates to an application of a protein kinase B inhibitor in preparation of a medicine for relieving inflammatory pain. By intrathecally injecting three dosages of Akt IV into L5-L6 sacrum gap 30 min before injecting the BmK 1, the relieving effects of different dosages of Akt IV in the phenomenon such as experimental spontaneous pain, paroxysmal pain sense grand mal, bilateral mechanical pain sensitive and unilateral heat pain sensitive are researched. The protein kinase B inhibitor is built on an experimental animal inflammatory pain model and a basis for researching the Akt signal pathway related analgesic molecular mechanism and developing a novel analgesic medicine is provided.

The invention relates to a device, system and method to ablate a cardiac tissue. An ablation catheter system for drug refractory symptomatic paroxysmal atrial fibrillation (PAF). The system can include an elongated body; an electrode assembly comprising a shell configured with an inner chamber and a wall defining a proximal portion and a distal portion, the wall of the distal portion having at least one aperture; and a micro-element extending through the inner chamber between the proximal portion and the distal portion, the micro-element having a distal end received in the at least one aperture, the distal end being at least coextensive with an outer surface of the wall. The system is configured to achieve acute procedural PVI success for all patients of a predetermined patient population suffering from PAF.